Petrelintide

Investigated uses

• Obesity, overweight and type 2 diabetes in clinical development.

Mechanism and hypotheses

• Petrelintide is a long-acting amylin analogue being studied as a once-weekly investigational therapy.

Human evidence

• The randomized Phase 2 ZUPREME-1 trial evaluated petrelintide against placebo in 493 adults with overweight or obesity. Limitations: The cited results were sponsor-reported topline findings; confirmatory Phase 3 evidence and regulatory review remain pending.

Safety highlights

• Safety and tolerability remain under investigation; no approved prescribing information exists.
• Long-term and uncommon risks are not established because no approved label or postmarketing record exists.

Regulatory context

Investigational; no FDA-approved petrelintide product.